Zatolmilast is an investigational allosteric inhibitor of the phosphodiesterase-4D (PDE4D) enzyme, currently under evaluation for the potential treatment of Fragile X syndrome and other neurodegenerative… Read more
Zatolmilast is an investigational allosteric inhibitor of the phosphodiesterase-4D (PDE4D) enzyme, currently under evaluation for the potential treatment of Fragile X syndrome and other neurodegenerative conditions. By selectively inhibiting PDE4D, this compound prevents the breakdown of cyclic AMP (cAMP), a critical signaling molecule involved in neuronal connectivity and cognitive function. To support essential analytical research, this category features high-quality reference standards, including the active pharmaceutical ingredient, identified process and degradation impurities, and relevant metabolites. Pharmaceutical laboratories and researchers utilize these materials for impurity profiling, method validation, and rigorous quality control protocols. The collection also provides stable isotope labelled compounds, which serve as critical tools for mass spectrometry-based assays, ensuring accuracy and precision when quantifying the drug and its related substances in complex biological or chemical matrices.